Display options
Cite
Singhal J, Nagaprashantha L, Chikara S, et al. 2'-Hydroxyflavanone: A novel strategy for targeting breast cancer. Oncotarget. 2017;8(43):75025-75037doi: 10.18632/oncotarget.20499.
Singhal, J., Nagaprashantha, L., Chikara, S., Awasthi, S., Horne, D., & Singhal, S. S. (2017). 2'-Hydroxyflavanone: A novel strategy for targeting breast cancer. Oncotarget, 8(43), 75025-75037. https://doi.org/10.18632/oncotarget.20499
Singhal, Jyotsana, et al. "2'-Hydroxyflavanone: A novel strategy for targeting breast cancer." Oncotarget vol. 8,43 (2017): 75025-75037. doi: https://doi.org/10.18632/oncotarget.20499
Singhal J, Nagaprashantha L, Chikara S, Awasthi S, Horne D, Singhal SS. 2'-Hydroxyflavanone: A novel strategy for targeting breast cancer. Oncotarget. 2017 Aug 24;8(43):75025-75037. doi: 10.18632/oncotarget.20499. eCollection 2017 Sep 26. PMID: 29088842; PMCID: PMC5650397.
Copy Download .nbib Format: NLM
Share it on

Oncotarget. 2017 Aug 24;8(43):75025-75037. doi: 10.18632/oncotarget.20499. eCollection 2017 Sep 26.

2'-Hydroxyflavanone: A novel strategy for targeting breast cancer.

Oncotarget

Jyotsana Singhal, Lokesh Nagaprashantha, Shireen Chikara, Sanjay Awasthi, David Horne, Sharad S Singhal

Affiliations

  1. Department of Molecular Medicine, Beckman Research Institute of City of Hope, Comprehensive Cancer Center and National Medical Center, Duarte, CA 91010, USA.
  2. Department of Medical Oncology, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA.

PMID: 29088842 PMCID: PMC5650397 DOI: 10.18632/oncotarget.20499

Abstract

Breast cancer is the most common cancer in women that is driven by cross-talk with hormonal and cellular signaling pathways. The natural phytochemicals, due to broad-spectrum anti-inflammatory and anti-cancerous properties, present with novel opportunities for targeting breast cancer. Intake of citrus fruits is known to reduce the risk for incidence of breast cancer. Hence, we tested the efficacy of citrus flavonoid 2'-hydroxyflavanone (2HF) in breast cancer. 2HF inhibited survival, clonogenic ability, cell cycle progression and induced apoptosis in breast cancer cells. 2HF also decreased VEGF levels and inhibited migratory capacity of breast cancer cells. Administration of 2HF led to regression of triple-negative MDA-MB-231 tumors in the mice xenograft model. 2HF decreased the levels of RLIP76 both

Keywords: 2'-hydroxyflavanone; RLIP76; VEGF; breast cancer; xenografts

Conflict of interest statement

CONFLICTS OF INTEREST The authors declare that they have no conflicts of interest with the contents of this article.

References

  1. Lancet. 2002 Sep 14;360(9336):817-24 - PubMed
  2. Clin Cancer Res. 2008 Jul 15;14(14):4372-7 - PubMed
  3. Cancer Res. 2012 Oct 15;72(20):5165-73 - PubMed
  4. Int J Cancer. 2003 Sep 20;106(5):635-46 - PubMed
  5. J Agric Food Chem. 2008 Aug 13;56(15):6185-205 - PubMed
  6. J Nat Prod. 2003 Jul;66(7):1022-37 - PubMed
  7. Epidemiol Rev. 1993;15(1):36-47 - PubMed
  8. J Breast Cancer. 2013 Mar;16(1):72-6 - PubMed
  9. J Immunol Methods. 1993 Mar 15;160(1):81-8 - PubMed
  10. Breast Cancer Res Treat. 2016 Feb;155(3):463-9 - PubMed
  11. Cancer Treat Rev. 2008 Dec;34(8):701-9 - PubMed
  12. J Clin Invest. 2009 Jun;119(6):1420-8 - PubMed
  13. CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300 - PubMed
  14. Oncogene. 2003 Nov 24;22(53):8590-607 - PubMed
  15. J Biol Chem. 2015 Dec 18;290(51):30321-41 - PubMed
  16. PLoS One. 2013;8(1):e54318 - PubMed
  17. Mol Cancer Ther. 2011 Jan;10(1):16-28 - PubMed
  18. Eur J Cancer. 2009 Sep;45 Suppl 1:27-40 - PubMed
  19. Cancer Prev Res (Phila). 2011 Jun;4(6):879-89 - PubMed
  20. World J Clin Oncol. 2014 Aug 10;5(3):382-92 - PubMed
  21. Cancer Imaging. 2008 Nov 25;8:206-15 - PubMed
  22. Biochem Biophys Res Commun. 2006 Sep 22;348(2):722-7 - PubMed
  23. Carcinogenesis. 2011 Apr;32(4):568-75 - PubMed
  24. J Immunol Methods. 1983 Dec 16;65(1-2):55-63 - PubMed
  25. Cancer Res. 2007 May 1;67(9):4382-9 - PubMed
  26. Adv Exp Med Biol. 1998;439:227-36 - PubMed
  27. Int J Radiat Oncol Biol Phys. 2008 Oct 1;72 (2):553-61 - PubMed
  28. Biochemistry. 2000 Aug 8;39(31):9327-34 - PubMed
  29. Biochem Pharmacol. 2009 Mar 15;77(6):1074-83 - PubMed
  30. Nature. 2000 Sep 14;407(6801):242-8 - PubMed
  31. J Clin Oncol. 2005 Oct 10;23(29):7350-60 - PubMed
  32. Antioxid Redox Signal. 2013 Jul 10;19(2):163-80 - PubMed
  33. Annu Rev Public Health. 1996;17:47-67 - PubMed
  34. Clin Exp Pharmacol Physiol. 2004 Nov;31(11):786-90 - PubMed
  35. J Natl Cancer Inst. 1998 Sep 16;90(18):1371-88 - PubMed
  36. Cancer Res. 2006 Feb 15;66(4):2354-60 - PubMed
  37. Int J Clin Exp Pathol. 2015 May 01;8(5):5017-25 - PubMed
  38. J Biol Chem. 2008 Jul 11;283(28):19714-29 - PubMed
  39. Acta Haematol. 2001;106(4):148-56 - PubMed
  40. Ecancermedicalscience. 2013 Apr 18;7:307 - PubMed
  41. Cancer Causes Control. 2008 Jun;19(5):537-45 - PubMed
  42. Cancer Res. 2009 May 15;69(10):4244-51 - PubMed
  43. Breast Dis. 2010;32(1-2):35-48 - PubMed
  44. FEBS Lett. 2005 Aug 29;579(21):4635-41 - PubMed
  45. Lancet. 1995 Sep 30;346(8979):883-7 - PubMed

Publication Types

Grant support